Glucagon-like peptide-1 receptor (GLP-1R) agonists are currently utilized in the treatment of type II diabetes and obesity but may play a role in the treatment of IIMs. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.